Brand Reference: Tradjenta
| Metric | Verified Benchmark | Source |
|---|---|---|
| Linagliptin RxNorm Concept ID | 1100699 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $16.2000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $538.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $79.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $98.00 / mo | 9 Zero-PHI Verified Patient Logs |
Xanthine-scaffold competitive DPP-4 inhibitor exhibiting saturable high-affinity plasma binding and hepatobiliary clearance, preserving endogenous incretin peptides across all stages of chronic kidney disease without dose titration.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Linagliptin (Tradjenta, RxCUI 1100699) at $16.2000 per unit, whereas walk-in chain pharmacies bill cash patients an average of $538.00 monthly—creating a 82% ($440.00/mo) wholesale arbitrage spread down to $98.00.
Systemic exposure to Linagliptin reflects ~30% oral absorption kinetics and 90% eliminated unchanged via enterohepatic biliary excretion (< 5% renal), sustaining receptor engagement across a > 100 hours terminal / 12 hours effective accumulation half-life window (1.5 hours to peak >80% dpp-4 inhibition response profile).
Dosing protocols (5 mg PO once daily (no renal adjustment required)) balance efficacy (77.40% patient satisfaction across 9 logs) against nasal congestion (8% of reports), cough (6% of reports), arthralgia (5% of reports), with strict avoidance in hypersensitivity or bullous pemphigoid history on gliptins.
Across 9 verified cash-pay logs, Linagliptin achieves a 77.40% Worth-It rating with out-of-pocket spend averaging $98.00/mo versus $538.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 5 mg PO once daily (no renal adjustment required) for Linagliptin; monthly out-of-pocket dropped to $86.24 compared with $538.00 retail.
Completed 10 weeks on Linagliptin (5 mg PO once daily (no renal adjustment required)). Zero notable side effects on steady dosing.
Consistent biomarker response on 5 mg PO once daily (no renal adjustment required) Linagliptin sourced via TeleMed ($113.68/mo cash pay without insurance prior authorization).